Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
5.56
+0.78 (16.32%)
At close: Jun 6, 2025, 4:00 PM
5.49
-0.07 (-1.26%)
After-hours: Jun 6, 2025, 6:04 PM EDT
Sagimet Biosciences Employees
Sagimet Biosciences had 14 employees as of December 31, 2024. The number of employees increased by 4 or 40.00% compared to the previous year.
Employees
14
Change (1Y)
4
Growth (1Y)
40.00%
Revenue / Employee
n/a
Profits / Employee
-$4,079,571
Market Cap
179.01M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14 | 4 | 40.00% |
Dec 31, 2023 | 10 | 0 | - |
Dec 31, 2022 | 10 | 3 | 42.86% |
Dec 31, 2020 | 7 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
SGMT News
- 2 days ago - Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567 - Seeking Alpha
- 2 days ago - Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis - GlobeNewsWire
- 15 days ago - Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025 - GlobeNewsWire
- 4 weeks ago - Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne - GlobeNewsWire
- 3 months ago - Sagimet Biosciences' Denifanstat Should Be Worth More Today - Seeking Alpha
- 7 months ago - Sagimet: More Than Just A MASH Drug Development Biotech - Seeking Alpha